Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Tests like the one approved this week can show who is likely to be immune, but it’s not yet clear how long such immunity lasts.
A third of patients treated with Opdivo plus Yervoy experienced complete or partial tumor remission.
Gilead Sciences’ direct-acting antiviral regimen was previously approved for adults.
Acting Commissioner Ned Sharpless will return to lead the National Cancer Institute.
The indication for AbbVie’s regimen includes those with compensated cirrhosis.
September 4, 2019, the U.S. FDA released their recent approval of new dosage forms of Sovaldi and Harvoni for children 3 to 12 years of age.
Stella Armstrong’s journey to a healthier life wasn’t easy.
Between August 2018 and January 2019, the FDA doubled the number of liver cancer treatments.
A placebo-controlled study of obeticholic acid showed it improved liver fibrosis with no worsening of non-alcoholic steatohepatitis.
The U.S. FDA approved hepatitis C treatment Mavyret for children from ages 12 to 17 with all genotypes.
With the approval of Cyramza, there are now five targeted therapies for hepatocellular carcinoma.
The spray requires no medical training.
Cabometyx is the third liver cancer drug approved in the past six months.
Four out of 10 FDA workers are sidelined.
A second immunotherapy option is now available for hepatocellular carcinoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.